Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02034838 | Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study | PHASE1 | COMPLETED | 12 | — | — | Jan 1, 2014 | Sep 1, 2015 | Sep 22, 2015 | 1 | Canada |
main pharmacokinetic parameters of atazanavir: AUC0-24h, Cmax and Cmin.
| Arm | Type | Description |
|---|---|---|
| atazanavir 300mg boosted with ritonavir 100mg | EXPERIMENTAL | Two period drug interaction. Period one: atazanavir 300mg boosted with ritonavir 100 mg once daily as part of current treatment standard of care. Period two: atazanavir 300 mg boosted with ritonavir 50 mg once daily for study days 2-8 inclusive |
| Name | Type | Description |
|---|---|---|
| atazanavir 300mg boosted with ritonavir 50 mg | DRUG | atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9. atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8) |
Inclusion Criteria: * Patients meeting the following criteria will be eligible for participation in this study: 1. Signed informed consent prior to any study-related activities. 2. Documented HIV infection. 3. Male or female patients between 18 and 70 years of age inclusively. 4. Medicatio...